{"id":"NCT03176238","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer","officialTitle":"A Phase IIIb, Multi-center, Open-label Study of RAD001 in Combination With EXemestane in Post-menopausal Women With EStrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Locally Advanced or Metastatic Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-03-29","primaryCompletion":"2019-01-29","completion":"2019-01-29","firstPosted":"2017-06-05","resultsPosted":"2020-04-07","lastUpdate":"2020-04-07"},"enrollment":235,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Post Menopausal Breast Cancer"],"interventions":[{"type":"DRUG","name":"everolimus","otherNames":["RAD001"]},{"type":"DRUG","name":"exemestane","otherNames":[]}],"arms":[{"label":"everolimus + exemestane","type":"EXPERIMENTAL"}],"summary":"This international, multi-center, open-label, single-arm study evaluated the safety and tolerability profile of everolimus in post-menopausal women with HR positive, HER2 negative locally advanced or metastatic breast cancer after documented recurrence or progression following a non-steroidal aromatase inhibitors (NSAI) therapy in Novartis Oncology emergent growth market (EGM) countries.Data was presented by Asian countries vs Non-Asian countries to confirm no difference in safety and efficacy. Summary statistics were presented.","primaryOutcome":{"measure":"Summary of Number of Participants With Treatment Emergent Adverse Events (TEAE) - All Grades","timeFrame":"Baseline up to approximately 43 weeks for Asian countires and 32 weeks for Non-Asian countries including a 30 day post treatment follow up period","effectByArm":[{"arm":"Asian Everolimus + Exemestane","deltaMin":4,"sd":null},{"arm":"Non-Asian Everolimus + Exemestane","deltaMin":0,"sd":null},{"arm":"Total","deltaMin":4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":8},"locations":{"siteCount":55,"countries":["Australia","India","Indonesia","Jordan","Malaysia","Morocco","South Africa","South Korea","Taiwan","Thailand","Tunisia","Turkey (TÃ¼rkiye)","Vietnam"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":59,"n":199},"commonTop":["Stomatitis","Decreased appetite","Hyperglycaemia","Rash","Aspartate aminotransferase increased"]}}